Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights 
From Business Wire News Releases
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference 
From Business Wire News Releases
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Aimmune to Present at the Cantor Global Healthcare Conference
Aimmune to Present at the Cantor Global Healthcare Conference 
From Business Wire News Releases
FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory... 
From Business Wire News Releases
Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common... 
From Business Wire News Releases
Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases
From GlobeNewswire News Releases
Aimmune to Participate in Three Investor Conferences in September
Aimmune to Participate in Three Investor Conferences in September 
From Business Wire News Releases
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy 
From Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights 
From Business Wire News Releases
Aimmune to Present at the Wedbush PacGrow Healthcare Conference
Aimmune to Present at the Wedbush PacGrow Healthcare Conference 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy 
From Business Wire News Releases
Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy 
From Business Wire News Releases
Aimmune to Present at the JMP Securities Life Sciences Conference
Aimmune to Present at the JMP Securities Life Sciences Conference 
From Business Wire News Releases
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting 
From Business Wire News Releases
Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference 
From Business Wire News Releases
Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
DATA FROM TWO STUDIES CONFIRM QUALITY OF LIFE AND PSYCHOSOCIAL BURDEN OF LIVING WITH PEANUT ALLERGY 
From Business Wire News Releases
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year 
From Business Wire News Releases
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy 
From Business Wire News Releases
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress 
From Business Wire News Releases
New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
NEW STUDY SHOWS MORE THAN HALF OF TEENS WITH PEANUT ALLERGY VISITED THE E.R. 
From Business Wire News Releases
Aimmune to Present at RBC Capital Markets Global Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will... 
From Business Wire News Releases
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
AIMMUNE ANNOUNCES U.S. FDA ADVISORY COMMITTEE MEETING DATE FOR AR101 FOR PEANUT ALLERGY 
From Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference 
From Business Wire News Releases
European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
Aimmune Therapeutics’ European phase 3 trial of AR101 for peanut allergy met its primary endpoint. 
From Business Wire News Releases
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
The U.S. FDA has accepted the BLA filing of Aimmune Therapeutics’ AR101 for peanut allergy. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X